Elimination of Senescent Osteocytes by Bone‐Targeting Delivery of Β‐Galactose‐Modified Maytansinoid Prevents Age‐Related Bone Loss

Yi He,Lei Zhang,Xiang Chen,Bin Liu,Xiaoyan Shao,Depeng Fang,Jiaquan Lin,Na Liu,Yabing Lou,Jianghui Qin,Qing Jiang,Baosheng Guo
DOI: https://doi.org/10.1002/adhm.202302972
IF: 10
2023-12-09
Advanced Healthcare Materials
Abstract:The accumulation of senescent cells in bone during agbling contributes to senile osteoporosis and clearance senescent cells by senolytics could effectively alleviate bone loss. However, the applications of senolytics are limited due to their potential toxicities. Herein, we have modified small extracellular vesicles (sEVs) by incorporating bone‐targeting peptide, specifically (AspSerSer)6, to encapsulate galactose‐modified Maytansinoids (DM1). These modified vesicles are referred to as (AspSerSer)6‐sEVs /DM1‐Gal, and they have been designed to specifically clear the senescent osteocytes in bone tissue. In addition, the elevated activity of lysosomal β‐galactosidase (β‐gal) in senescent osteocytes but not normal cell in bone tissue could break down DM1‐Gal to release free DM1 for selective elimination of senescent osteocytes. Mechanically, DM1 could disrupt tubulin polymerization, subsequently induce senescent osteocytes apoptosis. Further, administration of bone‐targeting senolytics to aged mice could alleviate aged‐related bone loss without non‐obvious toxicity. Overall, this bone‐targeting senolytics could act as a novel candidate for specific clearance of senescent osteocytes, ameliorating age‐related bone loss, with a promising therapeutic potential for senile osteoporosis. This article is protected by copyright. All rights reserved
nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
What problem does this paper attempt to address?